Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 16912957.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Associations have been reported between an MDR1 variant and responses to nonnucleoside reverse-transcriptase inhibitors. We explored associations between MDR1, CYP2B6, and CYP3A polymorphisms and nevirapine hepatotoxicity. Among participants in a randomized study in South Africa (FTC-302), MDR1 3435C-->T was significantly associated with decreased risk of hepatotoxicity (risk ratio, 0.30; P=.016).
Medical subject headings
- Anti-HIV Agents
- Chemical and Drug Induced Liver Injury
- Cytochrome P-450 Enzyme System
- Genes, MDR
- Nevirapine
- Reverse Transcriptase Inhibitors